328-92-7Relevant academic research and scientific papers
Single C?F Bond Cleavage of Trifluoromethylarenes with an ortho-Silyl Group
Yoshida, Suguru,Shimomori, Ken,Kim, Youngchan,Hosoya, Takamitsu
supporting information, p. 10406 - 10409 (2016/08/24)
The transformation of a single C?F bond of trifluoromethylarenes bearing a hydrosilyl group at the ortho position was achieved. The activation of the hydrosilyl group with a trityl cation in the presence of nucleophiles allowed for selective C?F bond func
TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
-
Page/Page column 44, (2012/09/10)
The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthama, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases. (I)
A scaleable synthesis of dutasteride: A selective 5α-reductase inhibitor
Satyanarayana, Komati,Srinivas, Katkam,Himabindu, Vurimidi,Reddy, Ghanta Mahesh
, p. 842 - 845 (2012/12/30)
An improved and scaleable process for Dutasteride (1), a synthetic 4-azasteroid derivative essentially used for the treatment of prostate diseases, is described
Process for the preparation of 17beta-N-[2,5-bis(trifluoromethyl)phenyl] carbamoyl-4-aza-5-alpha-androst-1-en-3-one
-
Page/Page column 3; 4, (2008/06/13)
The present invention relates to a process for the preparation of Dutasteride, which is chemically known as 17β-N-[2,5-bis (trifluoromethyl) phenyl] carbamoyl-4-aza-5-α-androst-1-en-3-one and can be represented by Formula (I).
